Modality
Multispecific
MOA
WRNi
Target
WRN
Pathway
Amyloid
RCCParkinson's
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
~Mar 2017
→ ~Jun 2018
Phase 3
~Sep 2018
→ ~Dec 2019
NDA/BLA
Mar 2020
NDA/BLACurrent
NCT05998803
2,349 pts·RCC
2020-03→TBD·Recruiting
2,349 total pts1 indication
Approved
CompletedCurrentUpcoming
Trial Timeline
NDA/BLA
Recruit…
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05998803 | NDA/BLA | RCC | Recruiting | 2349 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 |